查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990132

导管相关血流感染疾病市场：按产品类型、涂层和最终用户划分 - 2026-2032年全球市场预测

Catheter-related Bloodstream Infections Market by Product Type, Coating, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，导管相关血流感染疾病市场价值将达到 18.4 亿美元，到 2026 年将成长至 19.4 亿美元，到 2032 年将达到 27.9 亿美元，复合年增长率为 6.08%。

主要市场统计数据
基准年 2025 18.4亿美元
预计年份：2026年 19.4亿美元
预测年份 2032 27.9亿美元
复合年增长率 (%) 6.08%

一个专注于临床要求、相关人员责任以及影响导管相关感染疾病预防和医疗设备引入的汇聚因素的框架。

导管相关血流感染在急诊和社区医疗机构中仍然是一个持续存在的挑战，它不仅造成了沉重的临床负担，也推动着医疗设备设计、临床实践和感染预防策略的不断创新。本文从病人安全需求、不断发展的医疗标准以及临床结果与采购和监管决策的交汇点来探讨这个问题。透过围绕技术、实践和政策展开讨论，相关人员将能够更有效地评估哪些干预措施能够带来最大的临床和营运价值。

医疗设备科学创新、实证通讯协定和跨部门合作如何汇聚一堂，重新定义感染预防策略和临床部署途径。

医疗系统、临床医生和製造商应对导管相关血流感染的方式正经历着重大变革。材料科学和表面工程的进步正在为器械层面带来新的防护能力，而插入技术、维护通讯协定和即时监测的逐步改进则正在改变临床工作流程。这些变革共同建构了一个更加多层次的感染控制系统，其范围不再局限于单一产品或操作，而是涵盖了整个医疗照护体系。

本研究评估了关税、采购、定价和供应商策略的变化如何影响感染预防产品的采购决策以及供应链的韧性。

美国近期关税调整为导管相关感染预防产品的供应链计算和采购决策引入了新的变数。其累积影响不仅限于价格调整，还波及供应商的筹资策略、库存管理以及国内製造商与国际供应商之间的竞争动态。采购团队被迫重新评估供应商多元化、双重采购和库存缓衝策略，以降低下游短缺和成本波动的风险。

详细的細項分析揭示了医疗设备类型、医疗环境和涂层技术如何相互交织，从而影响临床选择、采购和实施策略。

细分市场分析揭示了不同产品类型、终端用户和涂层方法的趋势差异，这些因素共同决定了产品的采用和创新重点。本研究基于产品类型，将中央静脉导管和周边静脉导管区分开来。中央静脉导管进一步分为非周边置入中央静脉导管和周边置入中央静脉导管，而周边静脉导管则包括中线导管和标准週边静脉导管。每个子类别都有其独特的临床适应症、留置时间方面的考虑以及影响器械选择和相关预防策略的风险特征。

关键地区法规结构、製造地和临床实践的多样性如何推动设备部署和分销策略的差异化？

区域趋势影响临床实践、监管重点和供应链结构，并对在美洲、欧洲、中东和非洲以及亚太地区营运的相关人员产生重大影响。在美洲，政策优先考虑品质指标和报销结果，迫使医疗机构优先考虑能够显着降低感染风险的干预措施。同时，强大的国内生产能力为许多地区的供应链持续性提供了保障。相较之下，欧洲、中东和非洲（EMEA）地区的环境更为多元化，法规结构、医疗基础设施成熟度和采购模式差异显着，因此需要製定针对特定区域的策略并结合本地证据来支持产品推广。

製造商和服务供应商之间采取竞争与合作并重的策略，优先考虑证据生成、整合解决方案和供应链弹性，以赢得临床机构的信任。

医疗设备製造商、涂层技术供应商和服务机构之间的竞争正在影响产品开发和打入市场策略。主要企业正投资于新一代材料和涂层化学技术，以提高抗菌性能，同时最大限度地减少对合理使用抗菌药物（AMS）倡议的影响。同时，随着製造商致力于提供包含医疗设备、培训和数位依从性工具的捆绑式解决方案，以改善临床疗效和客户维繫，产品组合也呈现出明显的多元化趋势。

为製造商和医疗保健系统提供切实可行的、基于证据的倡议，以加速改善临床结果、确保供应链连续性并安全地实施感染预防创新。

产业领导企业应采取切实可行的多面向策略来降低导管相关血流感染的发生率，平衡创新、推广应用和系统层面的变革。应优先投资于临床证据，以证明产品性能以及对感染率和资源利用的实际影响。除了医疗设备创新之外，还应进行前瞻性观察研究，并与医疗系统合作，以深入了解治疗效果和推广应用。

采用透明的混合方法，结合临床医生访谈、指南审查和透过三角验证进行检验整合，可以产生严谨且可操作的见解。

本分析的调查方法结合了第一手和第二手研究技术，以确保研究的严谨性、多方验证以及与相关人员的相关性。第一手研究包括对医疗保健专业人员、感染控制专家、采购经理和行业高管进行结构化访谈，以收集关于医疗设备性能、部署障碍和营运重点的第一手观点。除这些访谈外，还与监管专家和供应链经理进行了有针对性的讨论，以了解监管影响和物流方面的考虑。

策略整合强调，将创新、证据和营运严谨性结合，对于持续降低感染风险和提高病患安全至关重要。

总之，应对导管相关血流感染需要一项综合策略，该策略应将医疗设备创新、临床实践改进和价值链稳健性结合。导管设计和抗菌涂层的技术进步固然重要，但只有将其与严谨的证据收集、全面的培训以及支持合规性的运作体系相结合，才能真正发挥其价值。在各相关人员努力应对关税波动和区域差异之际，注重韧性、目标数据和协作实施将有助于区分有效和无效的项目。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：导管相关血流感染疾病市场：依产品类型划分

  • 中央静脉导管
    • 非周边置入中央静脉导管
    • 周边置入的中央静脉导管
  • 週边静脉导管
    • 中线导管
    • 标准週边静脉导管

第九章：导管相关血流感染疾病市场（依涂层划分）

  • 抗菌涂层
    • 抗生素浸渍
    • 氯己定涂层
    • 银涂层
  • 无涂层

第十章：导管相关血流感染疾病市场：依最终用户划分

  • 门诊手术中心
  • 居家照护设施
  • 医院

第十一章：导管相关血流感染疾病市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：导管相关血流感染疾病市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：导管相关血流感染疾病市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国导管相关血流感染疾病市场

第十五章：中国导管相关血流感染疾病市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advacare Pharma
  • AstraZeneca PLC
  • Bactiguard AB
  • Becton, Dickinson and Company
  • CorMedix Inc
  • Fresenius Medical Care AG
  • Glenmark Pharmaceuticals Ltd.
  • IntegraDose Compounding Services, LLC
  • Johnson & Johnson Services, Inc
  • JoinHub Pharma
  • Lupin Ltd.
  • Lyka Hetero Healthcare Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • TauroPhar GmbH
  • Xellia Pharmaceuticals Ltd.
Product Code: MRR-5D693B46C67B

The Catheter-related Bloodstream Infections Market was valued at USD 1.84 billion in 2025 and is projected to grow to USD 1.94 billion in 2026, with a CAGR of 6.08%, reaching USD 2.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.84 billion
Estimated Year [2026] USD 1.94 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 6.08%

A focused framing of clinical imperatives, stakeholder responsibilities, and the converging forces that shape catheter-related infection prevention and device adoption

Catheter-related bloodstream infections remain a persistent challenge across acute and community care environments, producing significant clinical burden and driving continuous innovation in device design, clinical practice, and infection prevention strategies. This introduction frames the issue in terms of patient safety imperatives, evolving standards of care, and the intersection of clinical outcomes with procurement and regulatory decision-making. By situating the discussion around technology, practice, and policy, stakeholders can more effectively assess where interventions will yield the greatest clinical and operational value.

Clinical teams face increasing pressure to reduce preventable infections as payers and regulators emphasize quality metrics and reimbursement-linked outcomes. At the same time, device manufacturers and hospital procurement leaders must balance clinical performance with cost containment and supply chain reliability. As a result, the landscape for catheter-related infection prevention is characterized by intensified collaboration between clinicians, infection preventionists, supply chain managers, and industry partners, fostering multidisciplinary solutions that integrate technology, training, and process optimization.

This introduction sets the stage for a detailed executive-level analysis by highlighting the key drivers that shape decision-making today: clinical efficacy of devices and coatings, procedural standards and bundles, workforce competency and adherence, and the broader economic and regulatory context that determines adoption pathways. By clarifying these themes up front, the subsequent sections can explore transformational shifts, segmentation dynamics, regional patterns, vendor strategies, and practical recommendations for leaders seeking to reduce infection risk while optimizing care delivery.

How innovations in device science, evidence-based protocols, and cross-sector collaboration are converging to redefine infection prevention strategies and clinical adoption pathways

Significant transformative shifts are reshaping how healthcare systems, clinicians, and manufacturers approach catheter-related bloodstream infections. Advances in material science and surface engineering are translating into new device-level protections, while incremental improvements in insertion technique, maintenance protocols, and real-time monitoring are altering clinical workflows. Together, these changes are creating a more layered defense against infection that extends beyond a single product or practice and toward integrated bundles of care.

Simultaneously, the role of evidence generation has intensified; high-quality comparative effectiveness research and pragmatic trials are influencing purchasing decisions and clinical guidelines, driving a movement from anecdote-driven adoption to data-driven implementation. Health systems are increasingly focused on measurable outcomes, which has elevated the importance of robust post-market surveillance and adoption of standardized infection tracking mechanisms. In parallel, digital health tools-ranging from electronic checklists to remote monitoring of catheter dwell times-are being piloted and, in some cases, scaled to support adherence and early detection of complications.

Moreover, cross-sector collaboration is becoming more prominent: manufacturers are partnering with clinicians and academic centers to co-develop protocols that optimize device use in real-world settings, and payers are engaging in value-based conversations that prioritize durable clinical benefit. Taken together, these transformative shifts are producing a dynamic environment where incremental technical advances, rigorous evidence, and system-level incentives coalesce to change both practice and procurement in infection prevention.

Assessing how tariff-driven shifts in sourcing, pricing, and supplier strategy are reshaping procurement decisions and supply chain resilience for infection prevention products

Recent tariff changes in the United States have introduced a new variable into supply chain calculus and procurement decision-making for catheter-related infection prevention products. The cumulative impact extends beyond simple price adjustments and touches vendor sourcing strategies, inventory management, and the competitive dynamics between domestic manufacturers and foreign suppliers. Procurement teams have been required to reassess supplier diversity, dual sourcing, and inventory buffers to mitigate the risk of downstream shortages or cost volatility.

Manufacturers facing higher input costs and potential import levies have responded with a mix of nearshoring, renegotiation with component vendors, and targeted price realignments. These responses, in turn, influence hospital purchasing behavior, encouraging longer-term contracting, increased emphasis on total cost of ownership, and more rigorous supplier performance metrics. In some cases, health systems are accelerating adoption of products with proven efficacy that can reduce length of stay or complication-related resource use, thereby offsetting incremental acquisition costs.

Regulatory and policy stakeholders have also adapted by issuing guidance to ensure continuity of care and to prioritize supply chain transparency. Meanwhile, industry participants are exploring collaborative procurement consortia and pooled purchasing arrangements to preserve purchasing leverage and normalize access across different facility types. The net effect is a market that is more attuned to supply chain resilience and value-driven procurement, with organizations balancing cost pressures against the clinical imperative to prevent avoidable bloodstream infections.

Deep segmentation insights revealing how device type, care setting, and coating technologies intersect to shape clinical selection, procurement, and implementation strategies

Segment-level analysis reveals distinct dynamics across product type, end user, and coating modality that collectively inform adoption and innovation priorities. Based on product type, the landscape differentiates between central venous catheters and peripheral venous catheters, with central venous catheters further divided into non-peripherally inserted central catheters and peripherally inserted central catheters, while peripheral venous catheters encompass midline catheters and standard peripheral intravenous catheters; each subcategory presents unique clinical indications, dwell time considerations, and risk profiles that influence device selection and adjunctive prevention strategies.

Based on end user, utilization and purchasing pathways vary across ambulatory surgical centers, home care settings, and hospitals, with each setting imposing distinct logistic, staffing, and training constraints. Hospitals typically centralize infection control expertise and have established procurement infrastructures, whereas ambulatory surgical centers and home care settings may prioritize devices that are simple to use, require minimal maintenance, and support rapid patient turnover or remote management.

Based on coating, differentiation between antimicrobial coated and non-coated devices is a critical axis. The antimicrobial coated segment is further characterized by antibiotic-impregnated, chlorhexidine coated, and silver coated options, each offering different spectra of antimicrobial activity, longevity, and regulatory considerations. These coating choices interact with clinical protocols and stewardship priorities, influencing clinician preference, formulary decisions, and post-market surveillance requirements. Understanding how these segmentation dimensions intersect is essential for stakeholders aiming to optimize clinical outcomes while aligning with operational needs and stewardship goals.

How regional regulatory frameworks, manufacturing footprints, and clinical practice variability across key geographies drive differentiated strategies for device adoption and distribution

Regional dynamics influence clinical practice, regulatory emphasis, and supply chain architecture in ways that matter to stakeholders operating across Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, policy emphasis on quality metrics and reimbursement-linked outcomes has pushed institutions to prioritize interventions with demonstrable reductions in infection risk, while robust domestic manufacturing capacity has supported supply chain continuity in many areas. In contrast, Europe, Middle East & Africa present a more heterogeneous environment where regulatory frameworks, health infrastructure maturity, and procurement models vary significantly, driving the need for region-specific strategies and localized evidence to support product adoption.

Asia-Pacific is characterized by rapid infrastructure expansion, growing clinical capacity in both acute and community care, and an increasing focus on infection prevention as standards evolve. Supply chain dynamics across these regions differ as well, with Asia-Pacific often serving as a key manufacturing hub and the Americas and Europe representing large, sophisticated demand centers. These regional contrasts create opportunities for tailored go-to-market approaches that account for regulatory pathways, local clinical practice patterns, and distribution network realities.

Consequently, companies and health systems should calibrate their regional engagement strategies to reflect differences in evidence requirements, procurement cycles, and implementation capacity. Regional partnerships, targeted clinical data generation, and adaptive distribution models are typically most effective when they align with the specific operational and regulatory contours of each geography.

Competitive and collaborative strategies among manufacturers and service providers that prioritize evidence generation, integrated solutions, and supply chain resilience to gain clinical trust

Competitive activity among device manufacturers, coating technology providers, and services organizations is shaping both product development and market engagement strategies. Leading players are investing in next-generation materials and coating chemistries that improve antimicrobial performance while minimizing impact on antimicrobial stewardship initiatives. At the same time, portfolio diversification is evident as manufacturers seek to offer bundled solutions that combine devices, training, and digital adherence tools to strengthen clinical outcomes and customer retention.

Strategic partnerships between industry and clinical centers of excellence are increasingly common, facilitating real-world evidence generation and supporting guideline inclusion. Meanwhile, contract manufacturers and logistics providers are evolving their service offerings to address resilience concerns by providing dual-sourcing options, localized inventory hubs, and enhanced traceability. Mergers and acquisitions activity continues to reflect a desire to integrate novel coating technologies and point-of-care monitoring capabilities into broader product suites, enabling companies to offer differentiated value propositions to hospitals and alternative care sites.

Innovation in post-market surveillance and data analytics is also influencing competitive positioning, as companies that can demonstrate longitudinal safety and efficacy data gain traction with procurement committees and clinical leaders. Overall, the competitive landscape prizes agility in R&D, capacity to generate strong clinical evidence, and the ability to deliver comprehensive solutions that reduce infection risk across diverse care settings.

Practical, evidence-driven actions for manufacturers and health systems to enhance clinical outcomes, secure supply chain continuity, and accelerate safe adoption of infection prevention innovations

Industry leaders should adopt a pragmatic, multi-dimensional strategy to reduce catheter-related bloodstream infections that balances innovation, implementation, and system-level change. First, prioritize investment in clinical evidence that demonstrates not just product performance but real-world impact on infection rates and resource utilization. Complement device innovation with prospective observational studies and partnerships with health systems to capture meaningful outcomes and implementation insights.

Second, strengthen supply chain resilience through supplier diversification, contingency inventory strategies, and collaborative procurement models. Near-term tariff and trade uncertainties underscore the value of local manufacturing options and flexible sourcing arrangements, which can reduce exposure to single-source disruptions and support steady access to critical components and finished devices.

Third, integrate product adoption with workforce training and process redesign. Devices with advanced coatings or novel designs should be introduced alongside comprehensive competency programs, standardized insertion and maintenance bundles, and digital tools that support adherence and monitoring. Embedding change management and clear accountability in clinical pathways increases the likelihood that technical benefits translate into measurable reductions in infection risk.

Finally, engage proactively with regulators and payers to align on evidence requirements and reimbursement models that recognize the longer-term value of infection prevention. By taking a holistic approach that combines robust evidence, operational readiness, and adaptive procurement, leaders can accelerate safe adoption while managing cost and compliance pressures.

A transparent mixed-methods approach combining clinician interviews, guideline review, and triangulated evidence synthesis to produce rigorous and actionable insights

The research methodology underpinning this analysis leverages a blend of primary and secondary approaches to ensure rigor, triangulation, and relevance to stakeholders. Primary research comprised structured interviews with clinicians, infection prevention specialists, procurement leaders, and industry executives to capture first-hand perspectives on device performance, adoption barriers, and operational priorities. These interviews were complemented by targeted consultations with regulatory experts and supply chain managers to understand policy implications and logistics considerations.

Secondary research involved systematic review of peer-reviewed literature, clinical guidelines, and regulatory documents to contextualize primary findings within the broader evidence landscape. Where available, post-market surveillance reports, real-world evidence studies, and technical white papers were reviewed to assess safety and performance claims. Data synthesis prioritized cross-validation across sources to reconcile discrepancies and highlight consensus areas versus topics requiring further investigation.

Analytical techniques included qualitative thematic analysis to extract recurrent themes and drivers, as well as comparative assessment frameworks to evaluate relative strengths and limitations across device types, coatings, and care settings. Limitations of the methodology are acknowledged, including variability in published data granularity across regions and rapid innovation cycles that may alter the evidence base over short horizons. To mitigate these constraints, the study incorporated stakeholder validation and iterative review cycles to ensure findings remain robust and actionable.

A strategic synthesis underscoring the imperative of combining innovation, evidence, and operational rigor to consistently reduce infection risk and improve patient safety

In conclusion, addressing catheter-related bloodstream infections requires an integrated strategy that aligns device innovation, clinical practice improvement, and supply chain robustness. Technical advances in catheter design and antimicrobial coatings are important, but their full value is realized only when paired with rigorous evidence generation, comprehensive training, and operational systems that support adherence. As stakeholders navigate tariff-driven disruptions and regional variability, a focus on resilience, targeted data, and collaborative implementation will distinguish effective programs from those that fall short.

Leaders should therefore pursue coordinated investments: prioritize evidence that demonstrates clinical and operational benefit, build procurement strategies that minimize disruption risk, and embed change management into clinical rollouts. By doing so, health systems can protect patient safety while preserving financial sustainability, and manufacturers can create durable partnerships with customers grounded in measurable outcomes. The path forward emphasizes iterative learning, cross-sector collaboration, and a sustained commitment to translating technical promise into consistent, real-world reductions in infection risk.

These conclusions offer a strategic foundation for stakeholders ready to move from analysis to action, and the recommendations herein are intended to inform both near-term tactical decisions and longer-range strategic planning in the pursuit of safer vascular access care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-related Bloodstream Infections Market, by Product Type

  • 8.1. Central Venous Catheters
    • 8.1.1. Non-Peripherally Inserted Central Catheters
    • 8.1.2. Peripherally Inserted Central Catheters
  • 8.2. Peripheral Venous Catheters
    • 8.2.1. Midline Catheters
    • 8.2.2. Standard Peripheral Intravenous Catheters

9. Catheter-related Bloodstream Infections Market, by Coating

  • 9.1. Antimicrobial Coated
    • 9.1.1. Antibiotic Impregnated
    • 9.1.2. Chlorhexidine Coated
    • 9.1.3. Silver Coated
  • 9.2. Non-Coated

10. Catheter-related Bloodstream Infections Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. Catheter-related Bloodstream Infections Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Catheter-related Bloodstream Infections Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Catheter-related Bloodstream Infections Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Catheter-related Bloodstream Infections Market

15. China Catheter-related Bloodstream Infections Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Advacare Pharma
  • 16.6. AstraZeneca PLC
  • 16.7. Bactiguard AB
  • 16.8. Becton, Dickinson and Company
  • 16.9. CorMedix Inc
  • 16.10. Fresenius Medical Care AG
  • 16.11. Glenmark Pharmaceuticals Ltd.
  • 16.12. IntegraDose Compounding Services, LLC
  • 16.13. Johnson & Johnson Services, Inc
  • 16.14. JoinHub Pharma
  • 16.15. Lupin Ltd.
  • 16.16. Lyka Hetero Healthcare Ltd.
  • 16.17. Merck & Co., Inc.
  • 16.18. Novartis AG
  • 16.19. Pfizer Inc.
  • 16.20. Sanofi SA
  • 16.21. TauroPhar GmbH
  • 16.22. Xellia Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 141. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 142. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 148. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 149. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)